One such molecule is METTL3, increased METTL3 levels indicate poor prognosis in patients with CRC, including shorter disease‐free intervals, and undesirable clinicopathological factors such as pathological differentiation, AJCC stage, and disease recurrence.349, 353, 441. The gene discussed is METTL3; the disease is colorectal carcinoma.